CMV pneumonitis future or investigational therapies

	CMV pneumonitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating CMV pneumonitis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
CMV pneumonitis future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of CMV pneumonitis future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on CMV pneumonitis future or investigational therapies
CDC on CMV pneumonitis future or investigational therapies
CMV pneumonitis future or investigational therapies in the news
Blogs on CMV pneumonitis future or investigational therapies
Directions to Hospitals Treating CMV pneumonitis
Risk calculators and risk factors for CMV pneumonitis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Trials of ganciclovir with CMV IgG have not shown a consistent benefit in all studies.
Foscarnet is an alternative agent but data on its efficacy is lacking